Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Perturb-seq identifies co-regulated gene programs shaping hematopoietic stem and progenitor cell function

To sustain blood formation, hematopoietic stem and progenitor cells (HSPCs) coordinate a multitude of cell biological processes, from cell cycle control and stress responses to lineage priming. While many genetic regulators of high-level HSPC function have been identified, how HSPCs coordinate more basal cell biological programs, and how such programs relate to stem cell function, remains incompletely understood. Here we use Perturb-seq to profile the transcriptional consequences of targeting 520 genes by CRISPRi in primary mouse HSPC cultures. We developed an analytical strategy to separate perturbation-induced changes in cell-state abundance and clonal heterogeneity from cell-state-local transcriptional effects. From these local perturbation signatures, we identified 19 gene regulatory programs (GRPs) that are defined by co-regulation in response to genetic perturbation, in contrast to co-expression or human curation, and align well with cell biological processes. By decomposing gene expression data from functional and clinical studies into program activity, we show that GRP activities associate with, and predict, phenotypes such as clonal output after transplantation, as well as survival and drug response in retrospective acute myeloid leukemia (AML) cohorts. Together, our study establishes perturbation-derived co-regulation programs as an interpretable framework for linking genetic regulators, cell-biological processes and stem-cell-associated phenotypes.

Joseph S. Bowness, Aina Bernal Martínez, Jan Bařinka et al. · 0 citations
Open access Aug 2026

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.

T cell-mediated immune surveillance is critical for cancer control, yet its role in bone marrow malignancies remains poorly understood. Here, we integrate TCR profiling, HLA immunopeptidomics, and functional screening to characterize tumor-reactive T cells in the bone marrow of patients with multiple myeloma (MM) and acute myeloid leukemia (AML). These cells are transcriptionally defined by a conserved effector program distinct from the exhausted phenotype of tumor-reactive T cells in solid cancers. Immunopeptidomic profiling reveals a partially shared antigen landscape enriched for noncanonical peptides driving convergent TCR responses. We develop TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies these cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control. These findings reveal a latent but activatable anti-tumor T cell compartment in bone marrow malignancies and provide a framework for engaging endogenous immunity in MM and AML.

N. Kehl, T. Wagner, Simon Steiger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.